Technical Overview
Combining the patented NICSInst technology with the high-throughput next-generation sequencing, noninvasive Implantation Capability Screening (NICS®) test the cell-free DNA in the culture medium at blastocyst stage, by which physicians can obtain chromosomal ploidy information of the entire embryo without performing a biopsy, thus as a reference condition for selecting embryos for transplantation.